---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-149776"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2021-12-15T23:59:59+00:00"
generated_at: "2026-06-28T00:48:29.765008+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals appoints David Hollander, MD, MBA to its Board of Directors

## Summary
- Appointment effective December 13, 2021; press release issued December 15, 2021.
- Hollander is Chief R&D Officer at Aerie Pharmaceuticals, with extensive ophthalmic industry experience.
- He fills a vacancy created by board resignations in August 2021.
- Will serve as Class III director until 2024 Annual Meeting of Stockholders.
- Board determined he is independent under Nasdaq Capital Market rules.

## SEC filing metadata
- accession: 0001104659-21-149776
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2021-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000110465921149776/0001104659-21-149776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000110465921149776/tm2135455d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-149776
- JSON: https://secwatch.observer/filing/0001104659-21-149776.json
- Plain text: https://secwatch.observer/filing/0001104659-21-149776.txt

## Key facts
- Executive change
  David Hollander was appointed as Director at KIORA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Director
  source text: On December 13, 2021, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed David Hollander, MD, MBA as a member of the Board to fill a vacancy created by the previously disclosed resignations of two directors from the Board in August 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465921149776/0001104659-21-149776-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.